Business Context and Reporting Period
Filing identity: The supplied filing is Oculus Innovative Sciences, Inc.’s Form 10-K, not a Sonoma Pharmaceuticals, Inc. filing. It reports the fiscal year ended March 31, 2013, with fiscal 2012 as the comparable year; it is not a standalone 2012 Q4 report. Financial amounts below are in U.S. dollars.
Oculus develops and sells Microcyn-based wound-care, dermatology and animal-health products, alongside laboratory testing services. Its products were marketed in more than 20 countries. The company had U.S. medical-device clearances, but did not have FDA approval to market Microcyn as a drug or with antimicrobial or wound-healing claims in the United States.
Key Financial Metrics
| Metric | FY ended March 31, 2013 | FY ended March 31, 2012 |
|---|---|---|
| Total revenue | $15.452 million | $12.744 million |
| Gross profit | $10.743 million | $8.714 million |
| Operating loss | $3.374 million | $6.467 million |
| Net loss | $5.431 million | $7.329 million |
| Net cash from (used in) operations | $1.150 million | $(4.032) million |
| Cash and cash equivalents at year-end | $7.900 million | $3.351 million |
- Revenue rose 21%; product revenue, including licensing fees, increased 23% to $14.583 million. Service revenue was $0.869 million.
- Reported gross margin was approximately 69% on total revenue; product gross margin was reported as 73% of product revenue in MD&A. Licensing fees positively affected reported product margins.
- Research and development expense increased 12% to $2.223 million. Selling, general and administrative expense declined 10% to $11.894 million.
- Working capital was $6.407 million; total assets were $12.565 million and total liabilities were $8.484 million. Long-term debt had a $1.935 million net carrying value on the balance sheet; scheduled principal payments totaled $2.704 million, including $1.780 million due within one year.
- Accumulated deficit was $137.745 million. A $1.062 million deemed preferred dividend meant net loss available to common shareholders was $6.493 million, or $1.30 per share, versus $7.329 million, or $1.87 per share, in FY2012.
Material Changes Versus the Prior Year
- U.S. product revenue increased 45% to $6.842 million, driven by unit growth, dermatology launches and partner-related sales and royalties. Mexico product revenue increased 13% to $5.886 million, while Europe and rest-of-world product revenue declined 5% to $1.855 million.
- The More Pharma agreements in Mexico provided $5.1 million in upfront fees, recognized over an estimated three-to-five-year period; $0.932 million was recognized in FY2013. Revenue recognition for product sold to More Pharma shifted to sell-through, and lower unit pricing reduced Mexican gross margins. The transition also involved about $410,000 of one-time severance and related costs.
- Operating cash flow improved to positive $1.150 million, principally reflecting the More Pharma upfront payment and a $3.230 million increase in deferred revenue and other liabilities. Cash flow therefore should not be read as evidence of recurring operating profitability.
- The company issued shares to lenders in a debt and warrant restructuring. A $1.599 million non-cash loss reflected the year-end fair-value decrease in those shares. The company also recorded a $0.767 million non-cash gain from changes in derivative liabilities.
- A 1-for-7 reverse stock split became effective for market trading on April 1, 2013; share and per-share amounts in the filing are adjusted for it.
Outlook, Risks, and Unusual Items
- Management expected cash to support working capital, sales and marketing, and R&D through at least April 1, 2014, but anticipated continuing losses and possible need for additional financing. No financing commitment had been secured. U.S. pivotal trials were to be delayed pending a strategic funding partner or additional capital.
- Management expected R&D costs to rise over coming quarters and SG&A to decline as lower Mexico selling costs took effect. These are expectations, not guaranteed results.
- Ruthigen, a wholly owned subsidiary focused on hypochlorous-acid therapeutics, filed confidentially for a possible IPO after the proposed shareholder distribution was set aside partly because it was expected to be taxable. The offering and separation were not assured. Proposed agreements included milestone payments to Oculus totaling $8 million and royalties of 3%–20%, subject to development and approval.
- Principal risks include ongoing losses and funding needs; dependence on regulatory clearances and partners; customer and receivables concentration; reimbursement and market-adoption uncertainty; foreign-exchange exposure; manufacturing and product-compliance risks; and intellectual-property challenges. Two customers accounted for 25% and 13% of FY2013 revenue; three customers represented 34%, 26% and 15% of year-end receivables.
- A 2011 Class II labeling recall affected selected lots; the filing says costs were nominal and revenue was not materially affected. A lawsuit in Mexico was described by management as without merit; no loss reserve was recorded.
- The auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor was not engaged to audit internal-control effectiveness.
Important Facts for Investors to Verify
- Confirm the intended issuer: the provided filing is for Oculus Innovative Sciences, Inc., not Sonoma Pharmaceuticals, Inc.
- Review the audited statements and notes for the More Pharma fee recognition, deferred revenue, sell-through accounting and customer concentration.
- Assess cash runway against debt maturities, continuing losses, planned R&D and the absence of committed new financing.
- Check the status and terms of Ruthigen’s proposed IPO/separation, including the impact on Oculus’s licensed technology and future economics.
- Verify subsequent regulatory, commercial and financing developments; the filing’s forward-looking statements are not assurances of future results.